Efficacy of treatment with Ombitasvir, Paritaprevir / r + Dasabuvir over 8 versus 12 weeks in chronic HCV hepatitis genotype 1b

Efficacy of treatment with Ombitasvir, Paritaprevir / r + Dasabuvir over 8 versus 12 weeks in chronic HCV hepatitis genotype 1b

Background and aims. For the 8-week OPrD regimen, real world data are insufficient. This study aims to compare the efficacy of the two types of regimens (12-week versus 8-week) in a real world cohort of patients with genotype 1b. Material and methods. We analysed a multicentric retrospective cohort...

Full description

Bibliographic Details
Main Authors: Mircea Manuc, Carmen Monica Preda, Laura Iliescu, Doina Istratescu, Andreea Elena Chifulescu, Corina Silvia Pop, Anca Trifan, Carol Stanciu, Corneliu Petru Popescu, Mircea-Mihai Diculescu, Teodora Manuc, Letitia Tugui, Elena Cianga, Cristian George Tieranu, Tudor Stroie, Liliana Simona Gheorghe
Format: Article
Language:English
Published: Amaltea Medical Publishing House 2021-03-01
Series:Romanian Journal of Infectious Diseases
Subjects:
paritaprevir/ombitasvir/ritonavir/dasabuvir
chronic hepatitis
hepatitis c virus (hcv)
direct acting antiviral agents (daa)
Online Access:https://rjid.com.ro/articles/2021.1/RJID_2021_1_EN_Art-06.pdf

Similar Items

Similar Items